CRISPR Therapeutics AG filings document operating results, pipeline disclosures and capital-structure matters for a Swiss biopharmaceutical company developing gene-based medicines. Form 8-K reports furnish quarterly and annual financial results, business highlights for CASGEVY and investigational programs, clinical and regulatory updates across cardiovascular, autoimmune, immuno-oncology and regenerative medicine, and material-event disclosures.
The filing record also includes proxy materials covering shareholder voting and executive compensation, shelf-registration and prospectus-supplement disclosures for common-share offerings, and material definitive agreements for convertible senior notes due 2031. These filings describe common shares, equity financing mechanics, debt terms, governance matters and business disclosures tied to the company’s CRISPR/Cas9, LNP, CAR-T and siRNA platforms.
CRISPR Therapeutics AG director Simeon George exercised an option for 30,000 Common Shares at an exercise price of $14.0000 per share on October 14, 2026, and sold 14,514 Common Shares that day at a weighted-average price of $49.6330 per share. The sales were effected pursuant to a Rule 10b5-1 trading plan adopted on December 12, 2025.
Indirect holdings listed were 69,687 Common Shares held by SR One Fund II Aggregator, 238,897 held by SR One Opportunities Fund I, and 1,730,179 held by AMZL. George disclaims beneficial ownership of portions held by those entities in which he has no pecuniary interest.
CRISPR Therapeutics AG General Counsel and Secretary James R. Kasinger reported that 2,113 restricted stock units vested on October 13, 2026, resulting in 2,113 common shares. He sold 1,040 common shares on October 14, 2026, at $49.26 per share. The sale was required under the company’s RSU Settlement Policy to fund tax withholding and was not discretionary; no Rule 10b5-1 plan is reported.
CRISPR Therapeutics AG (CRSP) Chief Executive Officer Samarth Kulkarni received 8,333 Common Shares on October 13, 2026, when 8,333 restricted stock units vested. On October 14, 2026, he sold 4,098 Common Shares at $49.26 per share. The sale was required under the company's RSU Settlement Policy to fund tax withholding and was not a discretionary trade.
CRISPR Therapeutics AG director Simeon George reported a proposed sale of 14,514 common shares, with October 14, 2026, listed as the approximate sale date. The listed aggregate market value is $720,373.36; Morgan Stanley Smith Barney LLC is named as broker and NASDAQ as the exchange. The shares are listed as acquired from the issuer through a stock option exercise for cash on October 14, 2026.
CRISPR Therapeutics AG General Counsel and Secretary James R. Kasinger exercised options for 1,990 common shares on October 6, 2026, at a $13.62 exercise price, and sold 1,990 shares at a weighted average of $60.0408 per share. Sale prices ranged from $60.00 to $60.08, inclusive. His reported stock-option position after the transaction was 81,242 shares. The sales were made under a Rule 10b5-1 trading plan adopted May 6, 2026.
CRISPR Therapeutics AG officer James Kasinger reported a proposed sale of 1,990 common shares on October 6, 2026, with an aggregate market value of $119,481.19, through Morgan Stanley Smith Barney LLC. The shares are listed as acquired from the issuer on that date through a stock-option exercise for cash.
CRISPR Therapeutics AG General Counsel and Secretary James R. Kasinger exercised options covering 10,400 common shares on September 22, 2026, at an exercise price of $13.62 per share, acquired 10,400 shares, and sold 10,400 shares at a weighted average price of $60.2365 per share. The sales were made under a Rule 10b5-1 trading plan adopted May 6, 2026. The option transaction reported 83,232 shares following the exercise.
CRISPR Therapeutics AG (CRSP) received a notice that James Ramon Kasinger plans to sell common shares under Rule 144. The notice covers 10,400 common shares, to be sold through Morgan Stanley Smith Barney LLC, with an indicated aggregate value of $626,459.60 as of September 22, 2026, on NASDAQ.
CRISPR Therapeutics AG (CRSP) director Ali Behbahani exercised stock options for 30,000 Common Shares at $14.00 per share on September 17, 2026, and received 30,000 Common Shares. On the same date, he sold 13,679 Common Shares at a weighted average price of $57.0901 per share in multiple transactions at prices ranging from $56.97 to $57.43 per share. The exercised options were originally granted on October 18, 2016, vesting in 36 equal monthly installments beginning October 31, 2016. Following these transactions, an entity associated with him, The Ali Behbahani Revocable Trust Dated June 26, 2015, is reported as the direct beneficial owner of 29 Common Shares, with Behbahani as trustee and disclaiming beneficial ownership of any portion in which he has no pecuniary interest. No Rule 10b5-1 trading plan is reported for these transactions.
CRISPR Therapeutics AG (symbol: CRSP) is the issuer of record for a Form 4 filing submitted to the SEC. Behbahani Ali reported acquisition or exercise transactions in this Form 4 filing.
CRISPR Therapeutics AG (CRSP) director Ali Behbahani reported receiving Common Shares through an entity restructuring transaction on August 6, 2025. A pro rata distribution by NEA Partners 15, L.P. transferred 60 Common Shares to him directly, bringing his directly held position to 316 Common Shares.
The same distribution transferred 15 Common Shares to The Ali Behbahani Revocable Trust Dated June 26, 2015, resulting in 29 Common Shares held indirectly. He serves as trustee of the trust and disclaims beneficial ownership of any trust shares in which he has no pecuniary interest. No Rule 10b5-1 trading plan is reported.